Univest
Univest
  • Markets

Nifty Pharma Prediction for Tomorrow, 16 July 2026: Index Adds 0.37 Percent to 26,003.60, a Second Straight Positive Session

  • July 15, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments
Nifty Pharma Prediction for Tomorrow, 16 July 2026

Nifty Pharma prediction for tomorrow 16 July 2026: index at 26,003.60, up 0.37 percent on Wednesday, a second straight gain. Support 25,950. Resistance 26,100 and 26,250.

Nifty pharma prediction for tomorrow: Nifty Pharma closed at 26,003.60 on Wednesday, up 96.50 points or 0.37 percent, a second consecutive positive session that consolidates Tuesday’s strong 1.03 percent rally even as the sector’s leadership eased from the prior day’s standout pace. This nifty pharma prediction for tomorrow is built on Friday, 10 July 2026’s closing data, the last completed session before markets reopen on Monday, 13 July 2026.

Ankit Jaiswal, Senior Research Analyst at Univest, notes that the Nifty Pharma prediction for tomorrow reflects a sector holding onto its recent gains rather than reversing them, a healthier pattern than a single-day spike followed by giveback, even as Dr Reddy’s specifically bucked the broader sector strength.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Market Recap Behind the Nifty pharma prediction for tomorrow
  • Nifty pharma prediction for tomorrow: Trend and Key Levels
  • Global Cues for Nifty Pharma Tomorrow
  • Key Triggers in the Nifty pharma prediction for tomorrow
  • Stocks to Watch in the Pharma Sector
  • Risks to the Nifty pharma prediction for tomorrow
  • Conclusion
  • FAQs on the Nifty pharma prediction for tomorrow
    • What is the Nifty Pharma prediction for tomorrow, 16 July 2026?
    • Which analyst gave the Nifty Pharma prediction for tomorrow?
    • Is Nifty Pharma’s rally sustainable heading into this prediction for tomorrow?
    • Why did Dr Reddy’s fall while the broader pharma sector gained?

Market Recap Behind the Nifty pharma prediction for tomorrow

The index opened at 26,027.75, touched a high of 26,103.30 and a low of 25,950.10 before closing at 26,003.60. Ankit Jaiswal notes that while the broader pharma index posted a second straight gain, Dr Reddy’s Laboratories fell over 1 percent, a stock-specific divergence within an otherwise positive sector session.

Nifty pharma prediction for tomorrow: Trend and Key Levels

Trend: Bullish Above 25,950

Level Type Value
Support 1 25,950
Support 2 25,800
Resistance 1 26,100
Resistance 2 26,250

Ankit Jaiswal flags 25,950 as the key support, with 26,100 as the near-term resistance, matching Wednesday’s high. A close above 26,250 would confirm the sector’s rally has further room, while a break under 25,800 would suggest the two-session gains are beginning to fade.

Global Cues for Nifty Pharma Tomorrow

Iran shut the Strait of Hormuz again on Wednesday morning after the US announced fresh sanctions on Iranian ports, and Iran’s Revolutionary Guard launched missiles at two more oil tankers in the strait. Brent crude closed at its highest level since 12 June for a second straight session, even as softer-than-expected US inflation data and a firm Wall Street close helped Indian equities open sharply higher before the rally moderated through the day. The India-UK Free Trade Agreement also came into effect on Wednesday, expected to benefit labour-intensive export sectors. Pharma remains largely insulated from these geopolitical and currency-driven cues, since the sector’s fortunes depend more on US generic pricing trends and domestic demand, which continues to support its relative stability.

Key Triggers in the Nifty pharma prediction for tomorrow

These triggers dominate the outlook heading into Monday, 13 July 2026:

  • Continued sector consolidation: A third straight positive session would further confirm the defensive rotation has staying power.
  • Dr Reddy’s-specific weakness: Worth monitoring for whether this stock-specific decline widens or stays isolated.
  • HCL Technologies stabilised on Wednesday, up 0.11 percent to Rs 1,168, its first positive session since Tuesday’s sharp post-results decline.

Talk to a SEBI Registered Investment Advisor Before Your Next Trade

Stocks to Watch in the Pharma Sector

Key pharma constituents worth tracking alongside the broader sector outlook.

Sun Pharma: Sun Pharma is a sector bellwether worth tracking for stock-level signals within the pharma space.

Dr Reddy’s Laboratories: Fell over 1 percent on Wednesday, a notable stock-specific laggard within the otherwise positive sector.

Risks to the Nifty pharma prediction for tomorrow

These factors can invalidate this outlook:

  • Rotation reversal: If broader market sentiment strengthens further, defensive sectors like pharma could see some profit booking.
  • US regulatory setback: Any adverse FDA decision would be a clear sector-specific negative.
  • Widening stock-specific weakness: If more names follow Dr Reddy’s lower, it could eventually weigh on the broader index.

Download the Univest iOS App or Univest Android App to track live Nifty Pharma levels and get daily research from SEBI registered analysts.

Conclusion

The Nifty Pharma prediction for tomorrow, 16 July 2026, is bullish above 25,950, after the sector posted a second straight positive session, consolidating Tuesday’s strong rally. Ankit Jaiswal flags 25,950 as the key support in the Nifty Pharma prediction for tomorrow, with continued sector consolidation and Dr Reddy’s stock-specific weakness the key variables heading into Thursday.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on the Nifty pharma prediction for tomorrow

What is the Nifty Pharma prediction for tomorrow, 16 July 2026?

Ans. The Nifty Pharma prediction for tomorrow, 16 July 2026, is bullish above 25,950. The index closed at 26,003.60 on Wednesday, up 0.37 percent, a second straight positive session.

Which analyst gave the Nifty Pharma prediction for tomorrow?

Ans. Ankit Jaiswal, Senior Research Analyst at Univest, has shared the Nifty Pharma prediction for tomorrow, flagging 25,950 as the key support level.

Is Nifty Pharma’s rally sustainable heading into this prediction for tomorrow?

Ans. The Nifty Pharma prediction for tomorrow notes that a second straight positive session, even at a slower pace than Tuesday’s surge, is a healthier pattern than a single-day spike, suggesting the defensive rotation into pharma has some genuine staying power.

Why did Dr Reddy’s fall while the broader pharma sector gained?

Ans. Dr Reddy’s fell over 1 percent on Wednesday despite Nifty Pharma’s overall 0.37 percent gain, a stock-specific divergence the Nifty Pharma prediction for tomorrow flags as worth monitoring within an otherwise positive sector session.



News
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply